Occurrence of Multiple, Extensive and Pan Drug-Resistant Pseudomonas aeruginosa and Carbapenemase Production from Presumptive Isolates Stored in a Biobank at Ethiopian Public Health Institute

References

• FujitaniS, MoffettKS, YuV. Pseudomonas aeruginosa. Antimicrobe: infectious Disease & Antimicrobial Agents; 2017. Available from:http://www.antimicrobe.org/new/b112.asp. Accessed 819, 2021
   Google Scholar
• KaramiP, MohajeriP, MashoufRY, et al. Molecular characterization of clinical and environmental Pseudomonas aeruginosa isolated in a burn center. Saudi J Biol Sci. 2019;26(7):1731–1736. doi:10.1016/j.sjbs.2018.07.00931762651
   PubMed Web of Science ®Google Scholar
• TindallBJ, KämpferP, EuzébyJP, OrenA. Valid publication of names of prokaryotes according to the rules of nomenclature: past history and current practice. Int J Syst Evol Microbiol. 2006;56(11):2715–2720. doi:10.1099/ijs.0.64780-017082418
   PubMed Web of Science ®Google Scholar
• MooreNM, FlawsML. Introduction: pseudomonas aeruginosa. Clin Lab Sci. 2011;24(1):41. doi:10.29074/ascls.24.1.4121404963
   PubMedGoogle Scholar
• MeletisG, ExindariM, VavatsiN, SofianouD, DizaE. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia. 2012;16(4):303.23935307
   PubMed Web of Science ®Google Scholar
• OliverA, MuletX, López-CausapéC, JuanC. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resistance Updates. 2015;21:41–59. doi:10.1016/j.drup.2015.08.00226304792
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing.30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standard Institute; 2020.
   Google Scholar
• World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis; 2017. Available from:www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf?ua=1. Accessed 819, 2021.
   Google Scholar
• PhoenixBD. Laboratory procedure. latest released user manual; 2020:13–19.
   Google Scholar
• LancasterMV, FieldsRD. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents. Google Patents; 1996.
   Google Scholar
• BitewA. High Prevalence of Multi-Drug Resistance and Extended Spectrum Beta Lactamase Production in Non-Fermenting Gram-Negative Bacilli in Ethiopia. Infect Dis. 2019;12:1178633719884951.
   Google Scholar
• KumariM, KhuranaS, BhardwajN, MalhotraR, MathurP. Pathogen burden & associated antibiogram of Pseudomonas spp. in a tertiary care hospital of India. Indian J Med Res. 2019;149(2):295. doi:10.4103/ijmr.IJMR_14_1831219098
   PubMed Web of Science ®Google Scholar
• EnglandPH. Identification of Pseudomonas species and other NonGlucose Fermenters. UK Standards for Microbiology Investigations. ID 17 Issue 3; 2015. Available from:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/422699/ID_17i3.pdf. Accessed 819, 2021.
   Google Scholar
• MuluW, AberaB, YimerM, HailuT, AyeleH, AbateD. Bacterial agents and antibiotic resistance profiles of infections from different sites that occurred among patients at Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. BMC Res Notes. 2017;10(1):1–9.28057050
   PubMedGoogle Scholar
• DavaneM, SuryawanshiN, PichareA, NagobaBS. Pseudomonas aeruginosa from hospital environment. J Microbiol Infect Dis. 2014;4:01. doi:10.5799/ahinjs.02.2014.01.0124
   Google Scholar
• SaderiH, OwliaP. Detection of multidrug resistant (MDR) and extremely drug resistant (XDR) P. aeruginosa isolated from patients in Tehran, Iran. Iranian j Pathol. 2015;10(4):265.
   Google Scholar
• KateeteDP, NakanjakoR, NamugenyiJ, ErumeJ, JolobaML, NajjukaCF. Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007–2009). Springerplus. 2016;5(1):1–11. doi:10.1186/s40064-016-2986-726759740
   PubMedGoogle Scholar
• Abd El-BakyRM, MasoudSM, MohamedDS, et al. Prevalence and some possible mechanisms of colistin resistance among multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Infect Drug Resist. 2020;13:323. doi:10.2147/IDR.S23881132099423
   PubMed Web of Science ®Google Scholar
• Uc-CachónAH, Gracida-OsornoC, Luna-ChiIG, Jiménez-GuillermoJG, Molina-SalinasGM. High prevalence of antimicrobial resistance among gram-negative isolated Bacilli in intensive care units at a tertiary-care hospital in Yucatan Mexico. Medicina. 2019;55(9):588. doi:10.3390/medicina55090588
   Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/ EEA (EARS-Net) - Annual Epidemiological Report 2019. Stockholm: ECDC; 2020. Available from:https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2019.pdf. Accessed 819, 2021.
   Google Scholar
• MotbainorH, BerededF, MuluW. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study. BMC Infect Dis. 2020;20(1):92. doi:10.1186/s12879-020-4811-832000693
   PubMed Web of Science ®Google Scholar
• MekonnenH, SeidA, MollaG, GebrecherkosT. Antimicrobial Resistance Profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross sectional study; 2021.
   Google Scholar
• KanjSS, KanafaniZA, editors. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase–producing enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clinic Proceedings. Elsevier; 2011.
   Google Scholar
• PetraitisV, PetraitieneR, NaingE, et al. Ceftolozane-tazobactam in the treatment of experimental Pseudomonas aeruginosa pneumonia in persistently neutropenic rabbits: impact on strains with genetically defined mechanisms of resistance. Antimicrob Agents Chemother. 2019;63(9):344–319. doi:10.1128/AAC.00344-19.
   Web of Science ®Google Scholar
• FarrellDJ, FlammRK, SaderHS, JonesRN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57(12):6305. doi:10.1128/AAC.01802-1324100499
   PubMed Web of Science ®Google Scholar
• ChoJC, FiorenzaMA, EstradaSJ. Ceftolozane/Tazobactam: a Novel Cephalosporin/β‐Lactamase Inhibitor Combination. Pharmacotherapy. 2015;35(7):701–715. doi:10.1002/phar.160926133315
   PubMed Web of Science ®Google Scholar
• AuthorityM. Ethiopian Essential Medicines List; 2020. Available from:http://www.fmhaca.gov.et/wp-content/uploads/2020/12/EML-sixth-edition.pdf. Accessed 819, 2021.
   Google Scholar
• DijkmansAC, WilmsEB, KamerlingIM, et al. Colistin: revival of an old polymyxin antibiotic. Ther Drug Monit. 2015;37(4):419–427. doi:10.1097/FTD.000000000000017225549206
   PubMed Web of Science ®Google Scholar
• TsujiBT, PogueJM, ZavasckiAP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.30710469
   PubMed Web of Science ®Google Scholar
• World Health Organization. The detection and reporting of colistin resistance; 2018. Available from:https://apps.who.int/iris/bitstream/handle/10665/277175/WHO-WSI-AMR-2018.4-eng.pdf?sequence=1&isAllowed=y. Accessed 819, 2021.
   Google Scholar
• MagiorakosA-P, SrinivasanA, CareyR, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar